A 45-person healthcare technology startup had planned to wait until 2027 to stand up a formal compliance program. Customer security scrutiny and board pressure changed that timeline. The co-founder and CTO needed to launch a credible SOC 2 and HIPAA motion fast enough to satisfy enterprise customers and demonstrate to the board that the company's security posture was being handled responsibly. The challenge was doing it during a bridge round, with no budget allocated and cheaper alternatives on the table.
[ The Problem ]
Compliance Was Strategic, But the Budget Wasn't There Yet
The team had no hard regulatory deadline forcing their hand. What they had was a growing gap between what customers expected and what the company could prove. Security questionnaires from prospective customers were becoming a friction point, and without a SOC 2 or HIPAA program underway, the company had no credible answer.
The deeper problem was documentation. The CTO believed the company's technical controls were largely in place, but the absence of a structured compliance record made it impossible to demonstrate readiness to customers or auditors. For a company in a bridge round, every delayed enterprise conversation carried real commercial weight.
[ What they needed ]
Before selecting a platform, the team was trying to:
- Launch SOC 2 and HIPAA programs simultaneously rather than sequencing one after the other
- Surface documentation gaps quickly without a dedicated compliance team
- Give customers and security reviewers a self-serve way to evaluate the company's posture
- Identify a verified auditor path before committing to a platform
- Secure board approval for an unbudgeted project during a capital-constrained period
- Close a vendor decision before being pulled into additional evaluation cycles
[ Why Drata won ]
Speed to a board-approvable compliance program was the deciding factor, and Drata was the only vendor that made credibility and commercial flexibility work together.
Audit credibility was non-negotiable for this buyer: the CTO explicitly argued internally that a cheaper tool risked producing compliance outputs customers would not trust. Drata's verified auditor network and market reputation gave him a defensible position with the board that lower-cost alternatives could not match.
Dual-framework scope from day one: the buyer wanted SOC 2 and HIPAA running in parallel, not sequenced. Drata packaged both without requiring the company to phase or delay one program, which was a direct fit requirement no competitor addressed on the same terms.
Commercial structure designed for board approval: quarterly payment terms on a two-year agreement landed the total cost inside the range the CTO had disclosed as approvable. That structure converted buyer preference into a signed agreement without requiring a procurement process the company was not set up to run.
Execution speed closed the window before a competing evaluation could open: the CTO had not meaningfully engaged a competing vendor and wanted to finalize before being pulled into additional demos. Drata's responsiveness on pricing and terms gave the internal champion a way to end the process on his own terms.
[ How Drata solved it ]
Drata GRC gave the CTO a structured path to SOC 2 and HIPAA readiness simultaneously, with automated evidence collection that addressed the documentation gap without requiring a dedicated compliance hire. Trust Center provided a customer-facing layer so that security reviewers could access compliance information directly, reducing the volume of inbound questionnaires the team would otherwise need to answer manually.
AI Questionnaire Assistance handled repeat security question types automatically, freeing the team to focus on control management and audit preparation. TPRM extended the compliance posture to third-party relationships, which mattered for a healthcare-adjacent company with vendor obligations under HIPAA. Drata also connected the company with verified auditors, giving the CTO a concrete audit path to present internally rather than an open-ended cost estimate.
[ Before and after Drata ]
Before Drata, the company had no compliance program in motion and no timeline more concrete than a multi-year deferral. Customer security reviews had no structured answer, and the board had no visibility into when that would change.
After, SOC 2 and HIPAA programs are running in parallel with a verified audit path defined, a customer-facing Trust Center live, and a compliance record being built in real time.
[ Business outcome ]
The company entered its SOC 2 and HIPAA programs with a defined audit path and a customer-facing Trust Center live from the start. Customer security conversations that previously had no structured answer now had a self-serve destination, reducing the manual burden on the technical team.
The CTO was able to present the board with a compliance program that was already in motion, not aspirational. The combination of credible audit partners, dual-framework coverage, and a finance-compatible payment structure gave leadership the confidence to approve the investment during a period of active capital preservation. The company moved from a planned 2027 compliance timeline to an active program in the current period.